tert-butyloxycarbonyl-phenylalanyl-prolyl-arginal has been researched along with efegatran in 5 studies
| Studies (tert-butyloxycarbonyl-phenylalanyl-prolyl-arginal) | Trials (tert-butyloxycarbonyl-phenylalanyl-prolyl-arginal) | Recent Studies (post-2010) (tert-butyloxycarbonyl-phenylalanyl-prolyl-arginal) | Studies (efegatran) | Trials (efegatran) | Recent Studies (post-2010) (efegatran) |
|---|---|---|---|---|---|
| 16 | 0 | 0 | 43 | 3 | 0 |
| Protein | Taxonomy | tert-butyloxycarbonyl-phenylalanyl-prolyl-arginal (IC50) | efegatran (IC50) |
|---|---|---|---|
| Prothrombin | Homo sapiens (human) | 0.0351 | |
| Prothrombin | Bos taurus (cattle) | 0.0089 | |
| Coagulation factor X | Homo sapiens (human) | 2.008 | |
| Coagulation factor X | Bos taurus (cattle) | 7.6 | |
| Plasminogen | Homo sapiens (human) | 0.3083 | |
| Tissue-type plasminogen activator | Homo sapiens (human) | 0.034 | |
| Cationic trypsin | Bos taurus (cattle) | 0.0065 | |
| Trypsin-1 | Homo sapiens (human) | 0.008 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagdy, D; Bajusz, S; Barabas, E; Dioszegi, M; Fittler, Z; Horvath, G; Juhasz, A; Szabo, G; Szell, E; Tomori, E | 1 |
| Callas, DD; Fareed, J | 1 |
| Gesellchen, PD; Growe, VG; Jackson, CV; Shuman, RT; Wilson, HC | 1 |
| Bajusz, S; Barabas, E; Szell, E | 1 |
| Callas, D; Fareed, J; Iqbal, O | 1 |
5 other study(ies) available for tert-butyloxycarbonyl-phenylalanyl-prolyl-arginal and efegatran
| Article | Year |
|---|---|
Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H.
Topics: Animals; Anticoagulants; Blood Coagulation Tests; Cattle; Dogs; Fibrinolysis; In Vitro Techniques; Oligopeptides; Rabbits | 1990 |
Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy.
Topics: Antifibrinolytic Agents; Antithrombin III; Antithrombins; Aprotinin; Arginine; Binding Sites; Boron Compounds; Enzyme Activation; Fibrinolysis; Heparin; Hirudins; Humans; Oligopeptides; Peptide Fragments; Pipecolic Acids; Protein C; Recombinant Proteins; Sulfonamides; Thrombin | 1995 |
Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis.
Topics: Animals; Antithrombins; Bleeding Time; Coronary Thrombosis; Disease Models, Animal; Dogs; Female; Hemodynamics; Heparin; Oligopeptides; Tissue Plasminogen Activator | 1993 |
Screening for fibrinolysis inhibitory effect of synthetic thrombin inhibitors.
Topics: Evaluation Studies as Topic; Fibrinolysin; Fibrinolysis; Oligopeptides; Streptokinase; Thrombin; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 1993 |
Comparison of the anticoagulant activities of thrombin inhibitors as assessed by thromboelastographic analysis.
Topics: Amino Acid Sequence; Anticoagulants; Antithrombins; Blood Coagulation; Drug Evaluation, Preclinical; Hirudins; Humans; Molecular Sequence Data; Oligopeptides; Recombinant Proteins; Thrombelastography; Thrombin; Thromboplastin | 1995 |